Hospital
Thedacare Medical Center - Wild Rose, INC
Thedacare Medical Center - Wild Rose, INC was paid $6.04M by Medicaid between Jan 2018 and Dec 2024, across 76 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoTHEDACARE MEDICAL CENTER - WILD ROSE, INC
WILD ROSE, WI 54984
WILD ROSE, WI 54984
33aNPI1043263999assigned 05/19/2006
33bProvider typeCritical Access Hospital
28Total paid$6.04M
24GClaims104,758
24DCodes billed76
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#23 of 48
Median peer was paid$4.30M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FLETT, WILLIAM controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,414 | $775K | |
| 2019 | 11,062 | $964K | |
| 2020 | 13,516 | $632K | |
| 2021 | 15,966 | $732K | |
| 2022 | 17,071 | $809K | |
| 2023 | 19,335 | $1.11M | |
| 2024incomplete | 13,394 | $1.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 7,073 | 5,746 | $1.41M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 3,680 | 2,846 | $897K |
| 96361 | Intravenous infusion, hydration; each additional hour | 15% | 1,395 | 1,082 | $893K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 14% | 3,377 | 2,871 | $866K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.3% | 1,156 | 967 | $502K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 629 | 528 | $224K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.1% | 723 | 559 | $189K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.0% | 624 | 406 | $178K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.4% | 389 | 284 | $144K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.3% | 736 | 631 | $141K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.5% | 9,233 | 6,867 | $89K |
| 83880 | <1% | 2,295 | 1,757 | $49K |
64 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,227 | $45K |
| 87631 | <1% | 552 | $44K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,851 | $33K |
| 80076 | <1% | 6,056 | $32K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 767 | $29K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 107 | $27K |
| 84484 | <1% | 3,200 | $19K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,246 | $17K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 636 | $16K |
| 80306 | <1% | 993 | $14K | |
| 80061 | Lipid panel | <1% | 1,211 | $13K |
| 83735 | <1% | 3,320 | $12K | |
| 83690 | <1% | 2,082 | $10K | |
| 81001 | <1% | 4,267 | $10K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 206 | $10K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 581 | $9K |
| 82550 | <1% | 2,591 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,092 | $9K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 26 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 891 | $7K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 487 | $7K |
| 85610 | <1% | 3,217 | $7K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 220 | $7K |
| 82553 | <1% | 1,688 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,825 | $5K |
| 86140 | <1% | 1,447 | $5K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 289 | $5K |
| 82077 | <1% | 515 | $5K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 12 | $4K |
| 82150 | <1% | 567 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,855 | $3K |
| 85380 | <1% | 416 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,278 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 25 | $2K |
| 99000 | <1% | 489 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 17 | $2K |
| 81025 | <1% | 79 | $2K | |
| 83605 | <1% | 284 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 109 | $2K |
| 85379 | <1% | 276 | $1K | |
| 87070 | <1% | 113 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,860 | $923.54 |
| 87634 | <1% | 15 | $912.19 | |
| 84703 | <1% | 145 | $859.58 | |
| 87040 | <1% | 109 | $410.04 | |
| 87650 | <1% | 14 | $309.08 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 41 | $231.99 |
| 36592 | <1% | 171 | $163.34 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,934 | $125.68 |
| 87088 | <1% | 36 | $123.96 | |
| 80143 | <1% | 18 | $120.63 | |
| 87186 | <1% | 18 | $60.49 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 899 | $35.01 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,087 | $17.89 |
| A9270 | Non-covered item or service | <1% | 143 | $14.43 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 66 | $10.65 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 130 | $6.20 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 504 | $3.93 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 412 | $0.03 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,676 | $0.01 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 13 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 14 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 16 | $0.00 |
| 96376 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFLETT, WILLIAM (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.